Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Altitude Life leads eFFECTOR's $40mm Series B round; increased to $56mm

Executive Summary

Altitude Life Science Ventures led a $40mm Series B round for cancer drug developer eFFECTOR Therapeutics Inc., and also joins the company's board. Additional new investors AbbVie Biotech Ventures and BioMed Venture took part, along with returning backers Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Venture Management, Osage University Partners, and Mission Bay Capital. Some of the proceeds will fund Phase I/II trials of eFT508 for solid tumors, and will also support multiple expansion arms for the project in solid tumors and lymphoma.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies